Forest and Glenmark's oglemilast fails in Phase II for COPD
This article was originally published in Scrip
Executive Summary
Forest Laboratories and Glenmark's oral phosphodiesterase-4 (PDE4) inhibitor oglemilast has failed to meet the primary endpoint in a Phase IIb dose-ranging study in patients with chronic obstructive pulmonary disease (COPD).